课题基金 / 基金详情

Search for new MDR modulator and analysis of its target molecule

Search for new MDR modulator and analysis of its target molecule
寻找新的MDR调节剂及其靶分子分析
批准号:
14572004
负责人:
AOKI Shunji
金额:
$2.18万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2002
资助国家:
日本
项目状态:
已结题
起止时间:
2002 至 2003

项目摘要

项目成果

AOKI Shunji的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
1) In the course of our study of bioactive substances from majine organisms, we focused on a search for reversing substances of multidrug-resistance (MDR) in tumor cells and isolated agosterol A from a marine sponge Spongia sp. We examined the action of agosterol A for both the P-gp-or MRP1-mediated MDR cells and clalified that agosterol A inhibited the drug transportation through P-gp and/or MRP1 by affecting those drug efflux pumps directly.2) From the structure-activity relationship study, each of the 3,4,6-acetoxyl groups and 11,22-hydroxyl groups was elucidated to be crucial for reversing MDR in tumor cells. Furthermore, we synthesized the 125I-labeled photoaffinity probe of agosterol A.3) We succeeded in photolabeling bf MRP1 using the synthtic photoaffinity probe of agosterol A.Interestingly, the probe showed the affinity to MRP1 only in the presence of glutathione. We found that the probe photolabeled the C-proximal molecule of MRP1 (C932-1531; TMD2). Based on photolabeling studies in the presence and absence of GSH using membrane vesicles expressing various truncated, co-expressed, and mutated MRP1s, we found that LO is the site on MRP1 which interacts with GSH. Furthermore, we demonstrated that the GSH-dependent binding site of the probe lies between amino acid 1223 and 1295, a region of MRP1 which includes'TM helix 17. Furthermore, our findings suggest that the charged amino acid Arg1249 is indispensable for MRP1 substrates interaction whereae the C terminal region (C1295-1531).
期刊论文(66)
专著(0)
科研奖励(0)
会议论文
M.Mukai, X.F.Che, T.Furukawa, T.Sumizawa, S.Aoki, X.Q.Ren, M.Haraguchi, Y.Sugimoto, M.Kobayashi, H.Takamatsu, S.Akiyama: "Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells."Cancer Sci.. 94. 557-563 (2003)
M.Mukai、X.F.Che、T.Furukawa、T.Sumizawa、S.Aoki、X.Q.Ren、M.Haraguchi、Y.Sugimoto、M.Kobayashi、H.Takamatsu、S.Akiyama:“逆转 STI571 的耐药性
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Xiao-Qin Ren, Shunji Aoki, et al.: "Positively Charged Amino Acid proximate to C-terminus of TM17 of MRP1 is Indispensable for GSH-dependent binding of Substrates and for transport of LTC4"Biochemistry. 41. 14132-14140 (2002)
任晓琴 (Xiao-Qin Ren)、青木俊二 (Shunji Aoki) 等人:“靠近 MRP1 TM17 C 末端的带正电荷的氨基酸对于 GSH 依赖性底物结合和 LTC4 的转运是不可或缺的”生物化学。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Shunji Aoki, et al.: "Structure-activity relationship of neuritogenic spongean acetylene alcohols, lembehynes."Tetrahedron. 58. 5417-5422 (2002)
Shunji Aoki 等人:“致神经源性海绵乙炔醇、lembehynes 的结构-活性关系。”四面体。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
Shunji Aoki et al.: "Brianthein A, a novel briarane-type diterpene reversing multidrug resistance in human carcinoma cell line, from the gorgonian Briareum excavatum"Tetrahedron. 57. 8951-8957 (2001)
Shunji Aoki 等人:“Brianthein A,一种新型 briarane 型二萜,可逆转人类癌细胞系的多药耐药性,来自柳珊瑚 Briareum excavatum”四面体。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
27
    Search of natural compound activating endogenous anti-angiogenesis factor as an anti-cancer agent.
    • 批准号:
      20510209
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.0万
    • 财政年份:
      2008
    • 负责人:
      AOKI Shunji
    • 依托单位:
    Search of cell cycle regulator as an anti-cancer agent, from marine invertebrates
    Search for New Anti-angiogenic Agents Targeting on Endothelial Cell Growth or Motility.
    • 批准号:
      16510159
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.3万
    • 财政年份:
      2004
    • 负责人:
      AOKI Shunji
    • 依托单位:
    国内基金
    海外基金
    P-glycoprotein与Rack1和Src相互作用并促进耐药乳腺癌细胞侵袭转移的分子机制研究
    • 批准号:
      81472474
    • 项目类别:
      面上项目
    • 资助金额:
      85.0万元
    • 批准年份:
      2014
    • 负责人:
      张飞
    • 依托单位: